Announcement on Voluntary Disclosure of Obtaining Report on Ethical Approval for Key Phase III Clinical Trials of 3rd-generation ALK Kinase Inhibitor SY-3505
· Issued by Shouyao Holdings Beijing Co. Ltd. Class A via Shanghai Stock Exchange
Announcement on Voluntary Disclosure of Obtaining Report on Ethical Approval for Key Phase III Clinical Trials of 3rd-generation ALK Kinase Inhibitor SY-3505
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
